Drug firm Aurobindo Pharma on Tuesday said it has received 10 observations from the US health regulator for its Unit 3 in Hyderabad.
The United States Food and Drug Administration (USFDA) conducted an inspection at company’s Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad, from May 13 to May 24, 2019, Aurobindo Pharma said in a filing to the BSE.
“The company has received a ‘Form 483’ with 10 observations,” it added.
None of the observations are repetitive and are more procedural in nature, Aurobindo Pharma said.
“The company will be responding to the USFDA within the stipulated time. The Form 483 will not have an impact on existing business of this facility,” Aurobindo Pharma said.
The drug firm, however, did not provide any details about the observations made by the regulator.
Shares of Aurobindo Pharma closed at Rs 654.10 on the BSE, down 0.48 per cent from its previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.